Global Healthcare Analyst

Tina Banerjee

Equity research analyst having 15+ years of experience, with an interest on fundamentally strong global healthcare companies. I have been helping investors to find future winners in healthcare space to grow their wealth by focusing on the strength and potential of the business models of the companies. My initiating coverage reports and pitch help investors to know ‘what to buy’, ‘why to buy’, and ‘when to buy’. My clients always remain on top of the sector with the help of my timely and detailed notes on earnings or any news update. I also provide broader view on the entire healthcare sector through periodic thematic reports.

Sysmex Corp (6869 JP): Hematology Drives Robust 1Q Performance and Guidance Raise; What Lies Ahead

Sysmex Corp (6869 JP): The US Tariff Wound Would Not Be Deep Enough

Sysmex Corp (6869 JP): Forex to Take Some Sheen Away off Growth in FY26; Japan Still Remains Key

Sysmex Corp (6869 JP): Expansion Plans In Brazil Looks Prospective, Yet Gets Tricky With Margins

Equity Bottom-Up

<ul>
<li>
<a href="https://www.smartkarma.com/entities/sysmex-corp" target="_blank" data-smartkarma-citation="entities:19333:1" rel="noopener">Sysmex Corp (6869 JP)</a> revenue dropped 2% YoY to ¥361.1B in 9MFY26. SG&amp;A expenses totaled ¥120.2B, up 9% YoY resulting in operating profit of ¥48.7B, down 28% YoY.</li>
<li>During 9MFY26, impacted by inventory adjustments China sales declined 20% YoY to ¥65.5B. In Japan, strong hematology instrument sales in 9MFY25 led to 14% YoY lower sales to ¥40.5B.   </li>
<li>For FY26, Sysmex revised their previous revenue guidance of ¥510B to ¥500B (down 2% YoY) mainly due to China impact and revised plans for medical robotics business in Japan.</li>
</ul>



Sysmex Corp (6869 JP) revenue dropped 2% YoY to ¥361.1B in 9MFY26. SG&amp;A expenses totaled ¥120.2B, up 9% YoY resulting in operating profit of ¥48.7B, down 28% YoY.
During 9MFY26, impacted by inventory adjustments China sales declined 20% YoY to ¥65.5B. In Japan, strong hematology instrument sales in 9MFY25 led to 14% YoY lower sales to ¥40.5B.   
For FY26, Sysmex revised their previous revenue guidance of ¥510B to ¥500B (down 2% YoY) mainly due to China impact and revised plans for medical robotics business in Japan.


Sysmex Corp (6869 JP): 9MFY26 Revenue Drop on China, Guidance Revised Downwards